NCT03457532View on ClinicalTrials.gov

A Phase I Study of SCC244 in Patients with Advanced MET Alterations Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

177

Participants

Timeline

Start Date

December 16, 2017

Primary Completion Date

September 22, 2023

Study Completion Date

September 22, 2023

Conditions
Advanced Solid Tumor
Interventions
DRUG

Gumarontinib Tablets

25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)

Trial Locations (1)

Unknown

Shanghai East hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Haihe Biopharma Co., Ltd.

INDUSTRY